TL;DR
While animal and cell models suggested that heparin could block the liver's reuptake of PCSK9—a key protein that raises "bad" cholesterol—a new human study finds no such effect. Researchers demonstrated that intravenous heparin administration does not significantly alter circulating PCSK9 levels in humans, casting serious doubt on the potential of targeting this specific molecular interaction for new cholesterol-lowering therapies.
What Problem Does This Paper Address?
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a major player in cardiovascular health. It acts as a "chaperone" that sends the low-density lipoprotein receptor (LDLR) to the cellular "trash can" (the lysosome) for degradation. Fewer receptors mean more LDL cholesterol stays in the blood, increasing the risk of heart disease.
While we have effective drugs to inhibit PCSK9, we still don't fully understand how the liver reabsorbs it from the bloodstream. Previous studies in mice and cell cultures indicated that heparan sulfate proteoglycans (HSPGs) on the surface of liver cells act as "landing pads" or co-receptors that help the liver pull PCSK9 back in. If this were true in humans, a drug like heparin (which mimics HSPGs) should be able to "clog" these landing pads, causing PCSK9 to accumulate in the blood rather than entering the liver. This paper tests whether this mechanism actually holds up in human patients.
Methods
The researchers conducted the HepBlock9 study, leveraging a "natural experiment" occurring during routine medical care. They collected remnant plasma samples from 160 patients undergoing cardiac catheterization at Zuckerberg San Francisco General Hospital.
The study design was a "before-and-after" comparison:
- Baseline: Blood was drawn before the patient received intravenous unfractionated heparin (UFH), a standard anticoagulant used during the procedure.
- Post-Treatment: Blood was drawn shortly after the heparin bolus.
- Analysis: PCSK9 concentrations were measured using a commercial ELISA (enzyme-linked immunosorbent assay).
The team also performed equivalence testing to see if the results were statistically "the same" and looked at a separate group of 22 patients receiving continuous heparin infusions for up to 24 hours to rule out time-dependent effects.
Datasets
The study relied on primary clinical data collected specifically for this research:
- Main Cohort: 160 subjects (predominantly male, ethnically diverse, high prevalence of heart disease).
- Continuous Infusion Group: 22 separate patients monitored at 6-hour and 24-hour intervals.
- Comparison Group: 12 subjects who were excluded from the main analysis because they had recently taken heparin-like products, used to check for baseline differences.
Key Insights and Ideas
- The Translation Gap: This paper highlights a classic "bench-to-bedside" disconnect. Mechanisms that appear robust in mice or petri dishes (like the PCSK9:HSPG interaction) don't always translate to human physiology.
- Heparin as a Molecular Probe: Instead of developing a new drug, the authors used a century-old medication (heparin) as a competitive inhibitor to probe a biological pathway in real-time.
- Rapid Kinetics: The researchers focused on acute (bolus) administration because PCSK9 has a remarkably short half-life in the blood—only about 5 minutes. If heparin were going to displace it, the effect should have been visible almost immediately.
- Therapeutic Dead End: By showing that heparin doesn't displace PCSK9, the study suggests that disrupting the PCSK9:HSPG interaction is unlikely to be a successful strategy for developing new cholesterol medications.
Key Results
- No Significant Change: The median plasma PCSK9 concentration was 113 ng/ml before heparin and 119 ng/ml after. Statistically, this difference was non-significant ($p = 0.83$).
- Statistical Equivalence: Equivalence testing provided 95% confidence that heparin administration does not raise PCSK9 levels by more than 4.7% of the baseline value.
- Subgroup Consistency: The lack of effect remained consistent across all analyzed subgroups, including age, sex, race, statin use, and renal function.
- Duration Doesn't Matter: Even with continuous 24-hour infusions, there was no significant change in PCSK9 levels, suggesting that the "null" result isn't just due to the heparin wearing off too quickly.
Limitations and Future Work
The authors acknowledge several limitations:
- Static Measurements: The study measured the total amount of PCSK9 in the blood but couldn't directly track the "flux" or movement of individual molecules between different body compartments.
- Acute vs. Chronic: While they tested up to 24 hours, they cannot definitively say what would happen with long-term, chronic HSPG blockade.
- Genetic Nuance: It is possible that the HSPG interaction matters more in individuals with specific, rare genetic variants of PCSK9, which this study was not powered to detect.
Future research may need to look closer at the specific arginine-rich region of the PCSK9 prodomain in humans to see if other co-receptors are doing the work that HSPGs do in other species.
Summary updated